NCT00062491已完成2 期
Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Overall Response
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
Karenitecin (BNP1350)
干预措施: Karenitecin (BNP1350) (Drug)
结局指标
主要结局
Overall Response
时间窗: start of treatment until progressive disease
次要结局
- Objective Tumor Response Rate(Start of treatment to date of response)
- Duration of Response(Date of response to date of progressive disease)
- Overall Survival(Randomization to date of death from any cause)
- Progression Free Survival(Randomization to disease progression)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Karenitecin (BNP1350) in Patients With Brain TumorsBrain NeoplasmsMalignant Neoplasms, BrainBrain TumorsNCT00062478BioNumerik Pharmaceuticals, Inc.40
已完成
2 期
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerRecurrent Ovarian CarcinomaPrimary Peritoneal CarcinomaNCT00054119Gynecologic Oncology Group27
进行中（未招募）
2 期
A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3Neuroendocrine TumorsNeuroendocrine CarcinomaNCT04524208Karsten Gavenis45
招募中
2 期
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsT-Cell NeoplasmLymphoproliferative DisordersNCT04858256University of Michigan Rogel Cancer Center100
招募中
2 期
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins LymphomaChronic Lymphocytic LeukaemiaNCT04728893Merck Sharp & Dohme LLC490